

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waivers under Section 712(c)(2)(B) of the Food, Drugs, and Cosmetic Act
and 18 U.S.C. §208 Particular Matter Waiver**

Thomas Pickering, M.D.

Committees: Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory
Committees

Meeting Date: December 13, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to data submitted by Merck & Co., Inc. to support the over-the-counter use of Mevacor (lovastatin) 20 milligrams (mg) a day to help lower cholesterol which may prevent a first heart attack, I am eligible to receive waivers under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	Nature	Magnitude
Unrelated Advisory Board	Competing firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of this interest the waivers are not valid.

_____/s/_____
Signature of SGE

_____/11/8/07_____
Date